12:00 AM
 | 
Dec 20, 2010
 |  BC Week In Review  |  Company News  |  Deals

Orexo, Boehringer Ingelheim deal

Orexo received a €6.5 million ($8.6 million) milestone payment from Boehringer under a 2005 deal to develop Orexo's prostaglandin E2 (PGE-2) inhibitors to treat...

Read the full 99 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >